Ascenta Signs Cancer Drug Deal with Ascentage, Its China Spin-off

Ascenta Therapeutics of the US has struck a deal to co-develop cancer drugs with Ascentage Pharma Group, a company with operations in Hong Kong and Shanghai. As the names suggest, the two companies are closely related. Astentage was Ascenta’s R&D operation in China until it was spun off last year. The companies contend their collaboration will use each entity’s complementary strengths and speed up the process of regulatory review. More details....